AI Article Synopsis
- Acromegaly is linked to a higher risk of certain cancers, particularly differentiated thyroid cancer (DTC), but the impact of acromegaly on DTC's clinical course is unclear.
- Researchers studied 14 patients with both acromegaly and DTC, comparing them to a control group of 14 DTC patients without acromegaly, matched by age and gender.
- The findings revealed that acromegaly's activity, along with factors like gender, age, and disease duration, did not influence the treatment response or prognosis of DTC, as all patients were in remission at the time of the study.
Article Abstract
Acromegaly is known to be associated with high incidence of malignancies probably due to the mitogenic effects of IGF-1. Differentiated thyroid cancer (DTC) is reported to be one of the most frequent malignancies associated with acromegaly. But there is no data about the clinical course of DTC in acromegalic patients. In this study, we evaluated the course of DTC in 14 acromegalic patients retrospectively. Fourteen papillary thyroid cancer patients without acromegaly, who were matched with the acromegalic patient group for age, gender and properties of thyroid cancer, were investigated as the control group. We identified no change in the course and treatment responses of DTC in association with the acromegaly activity, gender, age and disease duration, and all patients were found to be in remission for DTC at the time of investigation. Retrospective analysis of this cohort suggests that the activity of acromegaly may not affect the treatment responses and prognosis of coexisting DTC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-0915-1982 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!